Cargando…
Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment
PURPOSE: Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist used for treatment of chronic central serous chorioretinopathy which characterized by accumulation of subretinal fluid causing a localized area of retinal detachment. unfortunately, EPL suffers from poor oral bioavailabil...
Autores principales: | Abdelhakeem, Eman, El-Nabarawi, Mohamed, Shamma, Rehab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023249/ https://www.ncbi.nlm.nih.gov/pubmed/33787445 http://dx.doi.org/10.1080/10717544.2021.1902023 |
Ejemplares similares
-
Effective Ocular Delivery of Eplerenone Using Nanoengineered Lipid Carriers in Rabbit Model
por: Abdelhakeem, Eman, et al.
Publicado: (2021) -
Eplerenone Treatment in Chronic Central Serous Chorioretinopathy
por: Iqbal, Faisal, et al.
Publicado: (2021) -
Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature
por: Chatziralli, Irini, et al.
Publicado: (2018) -
Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy
por: Sadda, Srinivas R.
Publicado: (2020) -
Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone
por: Anderson, William J., et al.
Publicado: (2022)